Abstract
Mutations of tumor suppressor protein p53 are present in almost about 50% of all cancers. It has been reported that the p53 mutations cause aggregation and subsequent loss of p53 function, leading to cancer progression. Here in this study we focus on the inhibitory effects of cationic osmolyte molecules acetylcholine chloride, and choline on an aggregation prone 10 amino acid p53 mutant peptide WRPILTIITL, and the corresponding wildtype peptide RRPILTIITL in vitro. The characterization tools used for this study include Thioflavin- T (ThT) induced fluorescence, transmission electron microscopy (TEM), congo red binding, turbidity, dynamic light scattering (DLS), and cell viability assays. The results show that acetylcholine chloride in micromolar concentrations significantly inhibit p53 mutant peptide aggregation in vitro, and could be promising candidate for p53 mutant/ misfolded protein aggregation inhibition.
Keywords: Aggregation, acetylcholine chloride, p53 peptide, osmolytes, cancer, inhibition.
Graphical Abstract
Protein & Peptide Letters
Title:Inhibition of p53 Mutant Peptide Aggregation In Vitro by Cationic Osmolyte Acetylcholine Chloride
Volume: 24 Issue: 4
Author(s): Zhaolin Chen and Mathumai Kanapathipillai
Affiliation:
Keywords: Aggregation, acetylcholine chloride, p53 peptide, osmolytes, cancer, inhibition.
Abstract: Mutations of tumor suppressor protein p53 are present in almost about 50% of all cancers. It has been reported that the p53 mutations cause aggregation and subsequent loss of p53 function, leading to cancer progression. Here in this study we focus on the inhibitory effects of cationic osmolyte molecules acetylcholine chloride, and choline on an aggregation prone 10 amino acid p53 mutant peptide WRPILTIITL, and the corresponding wildtype peptide RRPILTIITL in vitro. The characterization tools used for this study include Thioflavin- T (ThT) induced fluorescence, transmission electron microscopy (TEM), congo red binding, turbidity, dynamic light scattering (DLS), and cell viability assays. The results show that acetylcholine chloride in micromolar concentrations significantly inhibit p53 mutant peptide aggregation in vitro, and could be promising candidate for p53 mutant/ misfolded protein aggregation inhibition.
Export Options
About this article
Cite this article as:
Chen Zhaolin and Kanapathipillai Mathumai, Inhibition of p53 Mutant Peptide Aggregation In Vitro by Cationic Osmolyte Acetylcholine Chloride, Protein & Peptide Letters 2017; 24 (4) . https://dx.doi.org/10.2174/0929866524666170123142858
DOI https://dx.doi.org/10.2174/0929866524666170123142858 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Significance of Pharmacogenetics and Pharmacogenomics Research in Current Medical Practice
Current Drug Metabolism Recent Progress in Research on Ribosome Inactivating Proteins
Current Protein & Peptide Science Isoindole Derivatives: Propitious Anticancer Structural Motifs
Current Topics in Medicinal Chemistry Regulatory Cross Talks of Bone Cells, Hematopoietic Stem Cells and the Nervous System Maintain Hematopoiesis
Inflammation & Allergy - Drug Targets (Discontinued) Editorial [Hot topic: Metal Chelation (Guest Editors: Paul V. Bernhardt & Des R. Richardson)]
Current Topics in Medicinal Chemistry Renal Solute Transporters and Their Relevance to Serum Urate Disorder
Current Hypertension Reviews nMET, A New Target in Recurrent Cancer
Current Cancer Drug Targets Immunoregulatory and Effector Activities of Nitric Oxide and Reactive Nitrogen Species in Cancer
Current Medicinal Chemistry Small Molecule Tyrosine Kinase Inhibitors: The New Dawn for Cancer Therapy
Letters in Drug Design & Discovery The Typical Metabolic Modifiers Conferring Improvement in Cancer Resistance
Current Medicinal Chemistry Bcl-2 Inhibitors: Emerging Drugs in Cancer Therapy
Current Medicinal Chemistry Targeting Histone Deacetylases for the Treatment of Immune, Endocrine & Metabolic Disorders
Endocrine, Metabolic & Immune Disorders - Drug Targets Hepatitis B Virus X Protein Modulates Chemokine CCL15 Upregulation in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Inhibition of Intercellular Communication between Prostate Cancer Cells by A Specific Anti-STEAP-1 Single Chain Antibody
Anti-Cancer Agents in Medicinal Chemistry Recent Advances Using Phosphodiesterase 4 (PDE4) Inhibitors to Treat Inflammatory Disorders: Animal and Clinical Studies
Current Drug Therapy Monoclonal Antibodies as Cancer Therapeutics
Recent Patents on Biotechnology Progress in Structure-Based Design of EGFR Inhibitors
Current Drug Targets Navigational Bronchoscopy in the Evaluation of the Peripheral Pulmonary Nodule.
Current Respiratory Medicine Reviews ES-MDA: Enhanced Similarity-based MiRNA-Disease Association
Current Protein & Peptide Science Recent Advances of Silver Nanoparticles in Cancer Diagnosis and Treatment
Anti-Cancer Agents in Medicinal Chemistry